BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema

Benha University60 enrolled

Overview

Diabetic macular edema degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab(BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea;Regeneron, Tarrytown,NY)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Macular Edema

Interventions

BEOVU intravitreal injectionDRUG

BEOVU intravitreal injection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diabetic macular edema Exclusion Criteria: * other causes of macular edema * other macular diseases

Locations (1)

INMC

Abu Dhabi, United Arab Emirates

RECRUITING

Outcomes

Primary Outcomes

Best corrected visual acuity (BCVA)

Change in BCVA in LOG MARS(logarithm minimum angle of resolution

Time frame: 12 months

Central Contacts

TAREK R ELHAMAKY, MD

CONTACT

+9712 443 8999 thamaky@ibnnafees.com

TAREK ELHAMAKY

CONTACT

+9712 443 8999 thamaky@ibnnafees.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.